Overview

This conference aims to educate practitioners and update their knowledge of advances in diagnosing and managing Hematologic Malignancies.

Learning Objectives

After participating in these activities, learners will be better able to:

• Discuss the advancements and optimal strategies for the use of bispecific T-cell engagers and other novel therapies in Non-Hodgkin Lymphoma
• Understand the novel advancements in CAR T Cell Therapy for Non-Hodgkin Lymphoma and Leukemias
• Explain how to optimize treatment selection in Multiple Myeloma, including the use of minimal residual disease in the therapeutic setting
• Recommend the latest treatment approaches in Acute Lymphoblastic and Acute Myeloid Leukemia

Target Audience

The target audience for this conference is medical oncologists, hematologists, pathologists, oncology nurses, fellows, residents, advanced practice providers, family practitioners, primary care practitioners, allied health professionals, and other providers interested in the care of patients with cancer.

Accreditation

Global Education Group designates these live activities for a maximum of 3.0 AMA PRA Category 1 Credits™ each. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.